4-30961A

Address to:

Assistant Commissioner for Patents Box Patent Application Washington, DC 20231

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **continuation** of prior Application No. PCT/EP 00/04562, filed May 19, 2000.

Applicant (or identifier): OKUNO ET AL.

Title: PHARMACEUTICAL COMPOSITIONS AND USES

## Enclosed are:

| Encid          | osea        | are.   |
|----------------|-------------|--|
| 1.<br>2.<br>3. |             | Specification (Including Claims and Abstract) - 30 pages Drawings - 3 sheets Declaration and Power of Attorney a. Newly executed (original or copy) b. Copy from a prior application (signed or with indication that original was signed) i. Deletion of Inventors Signed statement attached deleting inventor(s) named in the prior application |
| 4.             |             | Incorporation By Reference The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.   |
| 5.<br>6.       |             | Microfiche Computer Program (appendix)  Nucleotide and/or Amino Acid Sequence Submission  Computer Readable Copy  Paper Copy  Statement Verifying Identity of Above Copies   |
| 7.             |             | Preliminary Amendment  |
| 8.<br>9.       | H           | Assignment Papers (Cover Sheet & Document(s)) English Translation of   |
| 10.            |             | Information Disclosure Statement   |
| 11.            |             | Certified Copy of Priority Document(s)   |
| 12.<br>13.     | $\boxtimes$ | Return Receipt Postcard Other: unsigned inventor declaration and application data sheet  |
| $\boxtimes$    | Apr         | e right to elect an invention or species that is different from that elected in parent plication No. PCT/EP 00/04562 in the event of a restriction or election of species  |

Filing fee calculation:

is hereby reserved.

| ☐ Befo                                | ore calculating the fi<br>ore calculating the fi | ling tee, ple<br>ling fee, ple | ase er | nter the encl<br>ancel claims | osed | Prelii | minary / | 4men | ıdmeı | nt. |
|---------------------------------------|--|--------------------------------|--------|-------------------------------|------|--------|----------|------|-------|-----|
| Basic Filing Fee                      |  |                                |        |                               |      |        |          |      |       |     |
| Multiple Dependent Claim Fee (\$ 280) |  |                                |        |                               |      |        |          |      |       |     |
| Foreign Language Surcharge (\$ 900)   |  |                                |        |                               |      |        |          |      |       |     |
|                                       | For  | Number<br>Filed                |        | Number<br>Extra               |      |        | Rate     |      | \$    |     |
| Extra<br>Claims                       | Total Claims                                     | 10                             | -20    | 0                             | х    | \$     | 18       | =    | \$    |     |
|                                       | Independent<br>Claims                            | 4                              | -3     | 1                             | х    | \$     | 84       | =    | \$    | 84  |
|                                       |  |                                |        |                               | ТО   | TAL F  | FILING   | FEE  | \$    | 824 |

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$824. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (908) 522-6955.

Date: November 20, 2001

Carol A. Loeschorn Attorney for Applicants Reg. No. 35,590 Tel. No. (908) 522-6932

Respectfully submitted